Good MorningEquity markets gained over 1.0% on Friday to close at a new 1-year high. The move was inspired by softer-than-expected PCE price data that suggests the FOMC is near the end of its tightening cycle. The caution for investors is that inflation remains hot at 4.1% core, and the oil price is rising again. Oil prices underpin inflation; with WTI set to move to a multi-month high, inflation will accelerate again.
This week will be another trying 1 for investors. A host of earnings reports is due out this week on top of the monthly labor data. The NFP report is expected to show another solid increase in job creation and rising wages. The risk is two-fold; a hot figure will play into the idea that the FOMC is not through raising interest rates, while a cool 1 may foreshadow the recession that has loomed for the last year. Featured: What a Bargain... 4 "Cheap Stocks" (Trading Cheat Sheet-MP) 
|
Markets | |
If you've looked at stock charts, you've likely heard of or seen moving averages. Dynamic curvy lines that continuously rise and fall represent them on the charts.
You can glean much information from using moving averages. Moving averages are some of the most commonly used chart indicators.... Read the Full Story |
|
From Our PartnersMan who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more. | | Click here to learn more. |
|
Markets | | Shares of Exxon Mobil (NYSE: XOM) fell by as much as 1.8% during the early hours of Friday's trading session; the decline is happening on a day when the broader markets (namely the S&P 500) are up by a third of a percent. The initial reaction can be attributed to markets digesting the latest fig... Read the Full Story |
|
Stocks | |
In today's ever-evolving investment landscape, technology has emerged as a clear standout, surpassing the broader market with its remarkable performance year-to-date. YTD, popular technology ETF Invesco QQQ (NASDAQ: QQQ) is up 44%, while the SPDR S&P 500 ETF (NYSE: SPY) is ... Read the Full Story |
|
From Our PartnersTradeSmith, one of the world's most cutting-edge financial tech companies, just launched a breakthrough, new A.I. algorithm called An-E... and showed many of its past predictions and just how accurate they were (often precise to within a tenth of a percent). | You can see the power of An-E by going here |
|
Markets | |
Having led much of the equity rally this year, shares of tech titan Apple Inc (NASDAQ: AAPL) have taken a hiatus in recent weeks. They managed to tag a fresh all-time high on July 19, but as they head into the final trading day of July on Monday, they're less than $1 higher than where th... Read the Full Story |
|
Markets | |
Shares of trucking and logistics giant Saia Inc. (NASDAQ: SAIA) are rising by as much as 3% during Friday's trading session, closing the week with sizeable bullish momentum in the company. The reaction comes as the firm releases its second quarter 2023 earnings results, which flashed som... Read the Full Story |
|
|
Markets | | Asian shares mostly rose Tuesday, boosted by market optimism set off by a Wall Street rally despite lingering worries about inflation and regional growth. Investors were also watching for the policy decision by the Reserve Bank of Australia. Some forecasters are expecting a hike, but analysts at ING... Read the Full Story |
|
Markets | | Chinese leader Xi Jinping’s government is promising to drag the economy out of a crisis of confidence aggravated by tensions with Washington, wilting exports, job losses and anxiety among foreign companies about an expanded anti-spying law Read the Full Story |
|
Markets | | Europe's banking sector could withstand a severe economic downturn without depleting their financial buffers against losses, the European Central Bank said Friday.A survey of 98 large and medium-sized banks done by the ECB's supervisory arm in conjunction with the European Banking Authority showed t... Read the Full Story |
|
Markets | | Europe’s economy has grown modestly after months of stagnation, but higher interest rates designed to fight inflation are casting a shadow as they make it more expensive for households and businesses to borrow, invest and spend.The 20 countries that use the euro currency and their 346 million people... Read the Full Story |
|
Markets | | Ben Bernanke, the former chairman of the U.S. Federal Reserve, will lead a review of the Bank of England’s economic forecasting amid concern that inaccurate predictions about growth and inflation hampered the central bank’s efforts to combat Britain’s cost-of-living crisis Read the Full Story |
|
Monday's Early Bird Stock Of The Day Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. | View Today's Stock Pick |
|